Concepedia

Publication | Closed Access

Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.

72

Citations

0

References

2006

Year

David H. Henry, Beth Brooks, D. Case, Ellioth Fishkin, Reed Jacobson, A. M. Keller, Jonas Kügler, J O Moore, R T Silver, Anna Maria Storniolo,
PubMed

Abstract

r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy. After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.